valeant pharmaceuticals international, inc. form 6-k

More documents

Recommendations

Info

BIOVAIL CORPORATION INTERNATIONALPART II - OTHER INFORMATION1. OPERATIONAL INFORMATIONThe press releases issued by the Company in the 1996 second quarter are attached as the following exhibits:a) On April 3, 1996, the Company announced the regulatory approval of its Tiazac(R) product in the United Kingdom by the MedicinesControl Agency.b) On April 17, 1996, the Company reports its 1996 First Quarter Financial results.c) On May 22, 1996, the Company announced that the Soros led Investor Group acquired 20% of the Company previously held by ForestLaboratories.d) On July 17, 1996, the Company reported its 1996 Second Quarter and Six Month Financial results.e) On July 22nd, 1996, the Company announced that it has been issued a U.S. patent on the Company's Diltiazem Delivery System.2. LEGAL PROCEEDINGSFor detailed in<strong>form</strong>ation concerning legal proceedings, reference is made to Note 3 in the financial statement contained as part hereof.
SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by theundersigned thereunto duly authorized.Biovail Corporation InternationalAugust 15, 1996By Robert A. Podruzny------------------------------Robert A. PodruznyVice President - Finance andChief Financial Officer
Page 1 and 2: VALEANT PHARMACEUTICALSINTERNATIONA
Page 3 and 4: BIOVAIL CORPORATION INTERNATIONALQU
Page 6 and 7: BIOVAIL CORPORATION INTERNATIONALCO
Page 8 and 9: 3. CONTINGENCIESOn November 12, 199
Page 10 and 11: The gross margin on contract revenu
Page 14 and 15: [BIOVAIL LOGO]EXHIBIT "A"FOR:APPROV
Page 18 and 19: [BIOVAIL LOGO]EXHIBIT "B"FOR:APPROV
Page 22 and 23: [BIOVAIL LOGO]EXHIBIT "C"FOR:APPROV
Page 24 and 25: Eugene Melnyk, Chairman of the Boar
Page 28: [BIOVAIL LOGO]EXHIBIT "E"FOR:APPROV

valeant pharmaceuticals international, inc. form 6-k

Create successful ePaper yourself

Delete template?

Save as template?